216 related articles for article (PubMed ID: 12860412)
1. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5.
Liu F; Su Y; Li B; Zhou Y; Ryder J; Gonzalez-DeWhitt P; May PC; Ni B
FEBS Lett; 2003 Jul; 547(1-3):193-6. PubMed ID: 12860412
[TBL] [Abstract][Full Text] [Related]
2. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.
Town T; Zolton J; Shaffner R; Schnell B; Crescentini R; Wu Y; Zeng J; DelleDonne A; Obregon D; Tan J; Mullan M
J Neurosci Res; 2002 Aug; 69(3):362-72. PubMed ID: 12125077
[TBL] [Abstract][Full Text] [Related]
3. Activation of Cdk5/p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves microRNA-195 down-regulation.
Sun LH; Ban T; Liu CD; Chen QX; Wang X; Yan ML; Hu XL; Su XL; Bao YN; Sun LL; Zhao LJ; Pei SC; Jiang XM; Zong DK; Ai J
J Neurochem; 2015 Sep; 134(6):1139-51. PubMed ID: 26118667
[TBL] [Abstract][Full Text] [Related]
4. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator.
Hisanaga S; Saito T
Neurosignals; 2003; 12(4-5):221-9. PubMed ID: 14673209
[TBL] [Abstract][Full Text] [Related]
5. Glutamate treatment and p25 transfection increase Cdk5 mediated tau phosphorylation in SH-SY5Y cells.
Jämsä A; Bäckström A; Gustafsson E; Dehvari N; Hiller G; Cowburn RF; Vasänge M
Biochem Biophys Res Commun; 2006 Jun; 345(1):324-31. PubMed ID: 16678793
[TBL] [Abstract][Full Text] [Related]
6. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing.
Wen Y; Planel E; Herman M; Figueroa HY; Wang L; Liu L; Lau LF; Yu WH; Duff KE
J Neurosci; 2008 Mar; 28(10):2624-32. PubMed ID: 18322105
[TBL] [Abstract][Full Text] [Related]
7. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.
Shukla V; Skuntz S; Pant HC
Arch Med Res; 2012 Nov; 43(8):655-62. PubMed ID: 23142263
[TBL] [Abstract][Full Text] [Related]
8. Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene.
Patzke H; Maddineni U; Ayala R; Morabito M; Volker J; Dikkes P; Ahlijanian MK; Tsai LH
J Neurosci; 2003 Apr; 23(7):2769-78. PubMed ID: 12684463
[TBL] [Abstract][Full Text] [Related]
9. A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.
Zheng YL; Li BS; Amin ND; Albers W; Pant HC
Eur J Biochem; 2002 Sep; 269(18):4427-34. PubMed ID: 12230554
[TBL] [Abstract][Full Text] [Related]
10. The interaction of Munc 18 (p67) with the p10 domain of p35 protects in vivo Cdk5/p35 activity from inhibition by TFP5, a peptide derived from p35.
Amin ND; Zheng Y; Bk B; Shukla V; Skuntz S; Grant P; Steiner J; Bhaskar M; Pant HC
Mol Biol Cell; 2016 Nov; 27(21):3221-3232. PubMed ID: 27630261
[TBL] [Abstract][Full Text] [Related]
11. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
12. Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation.
Han P; Dou F; Li F; Zhang X; Zhang YW; Zheng H; Lipton SA; Xu H; Liao FF
J Neurosci; 2005 Dec; 25(50):11542-52. PubMed ID: 16354912
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus 9-mediated Cdk5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer's disease mouse model.
He Y; Pan S; Xu M; He R; Huang W; Song P; Huang J; Zhang HT; Hu Y
FASEB J; 2017 Aug; 31(8):3383-3392. PubMed ID: 28420695
[TBL] [Abstract][Full Text] [Related]
14. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells.
Nath R; Davis M; Probert AW; Kupina NC; Ren X; Schielke GP; Wang KK
Biochem Biophys Res Commun; 2000 Jul; 274(1):16-21. PubMed ID: 10903889
[TBL] [Abstract][Full Text] [Related]
15. A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation.
Zheng YL; Amin ND; Hu YF; Rudrabhatla P; Shukla V; Kanungo J; Kesavapany S; Grant P; Albers W; Pant HC
J Biol Chem; 2010 Oct; 285(44):34202-12. PubMed ID: 20720012
[TBL] [Abstract][Full Text] [Related]
16. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau.
Hashiguchi M; Saito T; Hisanaga S; Hashiguchi T
J Biol Chem; 2002 Nov; 277(46):44525-30. PubMed ID: 12226093
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity induces cleavage of p35 to p25 by calpain.
Lee MS; Kwon YT; Li M; Peng J; Friedlander RM; Tsai LH
Nature; 2000 May; 405(6784):360-4. PubMed ID: 10830966
[TBL] [Abstract][Full Text] [Related]
18. Cdk5, a therapeutic target for Alzheimer's disease?
Tsai LH; Lee MS; Cruz J
Biochim Biophys Acta; 2004 Mar; 1697(1-2):137-42. PubMed ID: 15023356
[TBL] [Abstract][Full Text] [Related]
19. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.
Patrick GN; Zukerberg L; Nikolic M; de la Monte S; Dikkes P; Tsai LH
Nature; 1999 Dec; 402(6762):615-22. PubMed ID: 10604467
[TBL] [Abstract][Full Text] [Related]
20. AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain.
Xu M; Huang Y; Song P; Huang Y; Huang W; Zhang HT; Hu Y
J Alzheimers Dis; 2019; 70(2):573-585. PubMed ID: 31256130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
